Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2011

Switzerland and Australia Approve Novartis’ MS Drug

  • The Swiss and Australian regulatory authorities have both cleared Novartis’ Gilenya® (fingolimod) as first-line disease-modifying therapy for patients with relapsing-remitting multiple sclerosis (RRMS). Novartis announced the approvals just three days after EMA’s Committee for Medicinal Products for Human Use separately recommended approval of the drug within the EU. The sphingosine 1-phosphate receptor (S1PR) modulator is already approved in the U.S. and Russia.

    Gilenya’s approval in Switzerland and Australia is based on data from what Novartis claims is the largest clinical trial program conducted in MS to date. Trial data showed that treatment with Gilenya reduced relapses by 52% after a year when compared with therapy using interferon beta-1a. A two-year study also showed Gilenya led to a 54% reduction in relapse rate when compared with placebo. Patients in this trial also demonstrated a 30% lower risk of disability progression after three months, and a 37% lower risk of disability progression after six months.

    Novartis has developed Gilenya under license from Mitsubishi Tanabe Pharma.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »